Gallant and MWI Partner on Veterinary Stem Cell Therapy
What happened
Animal health biotech company Gallant has announced a partnership with MWI Animal Health to deliver an anticipated FDA-conditionally approved stem cell therapy to veterinary clinics. The agreement establishes the first ultra-low temperature cold chain in veterinary medicine for an off-the-shelf regenerative therapy.
Why it matters
Gallant's therapy, sonruvetcel, is an allogeneic mesenchymal stromal cell therapy derived from the uterus of healthy feline donors. The company's lead candidate targets refractory feline chronic gingivostomatitis (FCGS), a severe and painful oral inflammatory disease. FCGS affects a significant portion of the feline population, with prevalence estimates ranging from 0.7% to 12%. The current standard of care often involves the extraction of most or all teeth, which leads to substantial improvement or resolution in about 70% to 80% of cases. However, 20% to 30% of cats show little to no improvement, leaving a critical need for alternative treatments. For cats with FCGS that do not respond to extractions, mesenchymal stem cell therapy has shown promise in clinical trials, with some studies indicating that over 60% of treated cats achieve remission. Gallant's product is on track for conditional FDA approval in early 2026. The partnership with MWI Animal Health leverages a vast distribution network. MWI, part of Cencora, is a major distributor of animal health products in the United States and the United Kingdom, operating numerous distribution centers that enable broad access to veterinary clinics. Recently, Covetrus agreed to acquire MWI, a move that will consolidate the U.S. veterinary distribution market to two major players. Establishing an ultra-low temperature cold chain is a critical and novel step for veterinary medicine. Cell therapies are "living drugs" that require storage at temperatures between -40°C and -86°C to maintain their viability and effectiveness, a logistical challenge that this partnership aims to solve for veterinary practices.
Key numbers
- FCGS affects a significant portion of the feline population, with prevalence estimates ranging from 0.7% to 12%.
- The current standard of care often involves the extraction of most or all teeth, which leads to substantial improvement or resolution in about 70% to 80% of cases.
- However, 20% to 30% of cats show little to no improvement, leaving a critical need for alternative treatments.
- For cats with FCGS that do not respond to extractions, mesenchymal stem cell therapy has shown promise in clinical trials, with some studies indicating that over 60% of treated cats achieve remission.
What happens next
- The company's lead candidate targets refractory feline chronic gingivostomatitis (FCGS), a severe and painful oral inflammatory disease.
- Recently, Covetrus agreed to acquire MWI, a move that will consolidate the U.S.
- Cell therapies are "living drugs" that require storage at temperatures between -40°C and -86°C to maintain their viability and effectiveness, a logistical challenge that this partnership aims to solve for veterinary practices.
Quick answers
What happened in Gallant and MWI Partner on Veterinary Stem Cell Therapy?
Animal health biotech company Gallant has announced a partnership with MWI Animal Health to deliver an anticipated FDA-conditionally approved stem cell therapy to veterinary clinics. The agreement establishes the first ultra-low temperature cold chain in veterinary medicine for an off-the-shelf regenerative therapy.
Why does Gallant and MWI Partner on Veterinary Stem Cell Therapy matter?
Gallant's therapy, sonruvetcel, is an allogeneic mesenchymal stromal cell therapy derived from the uterus of healthy feline donors. The company's lead candidate targets refractory feline chronic gingivostomatitis (FCGS), a severe and painful oral inflammatory disease. FCGS affects a significant portion of the feline population, with prevalence estimates ranging from 0.7% to 12%. The current standard of care often involves the extraction of most or all teeth, which leads to substantial improvement or resolution in about 70% to 80% of cases. However, 20% to 30% of cats show little to no improvement, leaving a critical need for alternative treatments. For cats with FCGS that do not respond to extractions, mesenchymal stem cell therapy has shown promise in clinical trials, with some studies indicating that over 60% of treated cats achieve remission. Gallant's product is on track for conditional FDA approval in early 2026. The partnership with MWI Animal Health leverages a vast distribution network. MWI, part of Cencora, is a major distributor of animal health products in the United States and the United Kingdom, operating numerous distribution centers that enable broad access to veterinary clinics. Recently, Covetrus agreed to acquire MWI, a move that will consolidate the U.S. veterinary distribution market to two major players. Establishing an ultra-low temperature cold chain is a critical and novel step for veterinary medicine. Cell therapies are "living drugs" that require storage at temperatures between -40°C and -86°C to maintain their viability and effectiveness, a logistical challenge that this partnership aims to solve for veterinary practices.
